MSOS: Trump's Green Light - Why Cannabis Stocks Are Surging On Rescheduling News (Rating Upgrade)

I am upgrading the AdvisorShares Pure US Cannabis ETF to a buy rating due to imminent regulatory catalysts. Potential cannabis rescheduling to Schedule III would eliminate 280e taxes, materially boosting MSO profitability and enabling re-ratings. MSOS offers concentrated exposure to leading U.S. multi-state operators, trading at attractive mid-single-digit EBITDA multiples.